Literature DB >> 24248604

What can be expected from antimicrobial de-escalation in the critically ill?

Marin H Kollef1.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24248604     DOI： 10.1007/s00134-013-3154-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  15 in total

1.  Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia.

Authors:  P J Dennesen; A J van der Ven; A G Kessels; G Ramsay; M J Bonten
Journal:  Am J Respir Crit Care Med       Date:  2001-05       Impact factor: 21.405

2.  Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay.

Authors:  Andrew F Shorr; Scott T Micek; Emily C Welch; Joshua A Doherty; Richard M Reichley; Marin H Kollef
Journal:  Crit Care Med       Date:  2011-01       Impact factor: 7.598

3.  De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock.

Authors:  J Garnacho-Montero; A Gutiérrez-Pizarraya; A Escoresca-Ortega; Y Corcia-Palomo; Esperanza Fernández-Delgado; I Herrera-Melero; C Ortiz-Leyba; J A Márquez-Vácaro
Journal:  Intensive Care Med       Date:  2013-09-12       Impact factor: 17.440

4.  Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes.

Authors:  Philipp Schuetz; Beat Mueller
Journal:  Intensive Care Med       Date:  2013-10-30       Impact factor: 17.440

5.  Reduction of broad-spectrum antibiotic use with computerized decision support in an intensive care unit.

Authors:  Karin A Thursky; Kirsty L Buising; Narin Bak; Lachlan Macgregor; Alan C Street; C Raina Macintyre; Jeffrey J Presneill; John F Cade; Graham V Brown
Journal:  Int J Qual Health Care       Date:  2006-01-13       Impact factor: 2.038

6.  Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department.

Authors:  Andrew F Shorr; Marya D Zilberberg; Richard Reichley; Jason Kan; Alex Hoban; Justin Hoffman; Scott T Micek; Marin H Kollef
Journal:  Clin Infect Dis       Date:  2011-11-21       Impact factor: 9.079

7.  Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia.

Authors:  Yuichiro Shindo; Ryota Ito; Daisuke Kobayashi; Masahiko Ando; Motoshi Ichikawa; Akira Shiraki; Yasuhiro Goto; Yasutaka Fukui; Mai Iwaki; Junya Okumura; Ikuo Yamaguchi; Tetsuya Yagi; Yoshimasa Tanikawa; Yasuteru Sugino; Joe Shindoh; Tomohiko Ogasawara; Fumio Nomura; Hideo Saka; Masashi Yamamoto; Hiroyuki Taniguchi; Ryujiro Suzuki; Hiroshi Saito; Takashi Kawamura; Yoshinori Hasegawa
Journal:  Am J Respir Crit Care Med       Date:  2013-10-15       Impact factor: 21.405

8.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.

Authors:  M H Kollef; G Sherman; S Ward; V J Fraser
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

9.  A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia.

Authors:  Scott T Micek; Suzanne Ward; Victoria J Fraser; Marin H Kollef
Journal:  Chest       Date:  2004-05       Impact factor: 9.410

10.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

Authors:  Jean Chastre; Michel Wolff; Jean-Yves Fagon; Sylvie Chevret; Franck Thomas; Delphine Wermert; Eva Clementi; Jesus Gonzalez; Dominique Jusserand; Pierre Asfar; Dominique Perrin; Fabienne Fieux; Sylvie Aubas
Journal:  JAMA       Date:  2003-11-19       Impact factor: 56.272
View more
  7 in total

1.  "Does this patient have…" "Is this patient at risk for infection with multidrug resistant bacteria?"

Authors:  Cristina Vazquez Guillamet; Marin H Kollef
Journal:  Intensive Care Med       Date:  2015-11-10       Impact factor: 17.440

2.  Focus on adequate antimicrobial treatment and de-escalation in the ICU.

Authors:  Dominique D Benoit; Gordon Doig; Jean-Francois Timsit
Journal:  Intensive Care Med       Date:  2016-09-29       Impact factor: 17.440

Review 3.  Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting.

Authors:  Werner C Albrich; Stephan Harbarth
Journal:  Intensive Care Med       Date:  2015-07-21       Impact factor: 17.440

Review 4.  Year in review in Intensive Care Medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics.

Authors:  Jean-François Timsit; Anders Perner; Jan Bakker; Matteo Bassetti; Dominique Benoit; Maurizio Cecconi; J Randall Curtis; Gordon S Doig; Margaret Herridge; Samir Jaber; Michael Joannidis; Laurent Papazian; Mark J Peters; Pierre Singer; Martin Smith; Marcio Soares; Antoni Torres; Antoine Vieillard-Baron; Giuseppe Citerio; Elie Azoulay
Journal:  Intensive Care Med       Date:  2015-03-26       Impact factor: 17.440

Review 5.  Treatment of bloodstream infections in ICUs.

Authors:  Jean-François Timsit; Jean-François Soubirou; Guillaume Voiriot; Sarah Chemam; Mathilde Neuville; Bruno Mourvillier; Romain Sonneville; Eric Mariotte; Lila Bouadma; Michel Wolff
Journal:  BMC Infect Dis       Date:  2014-11-28       Impact factor: 3.090

6.  Characteristics and outcomes of anti-infective de-escalation during health care-associated intra-abdominal infections.

Authors:  Philippe Montravers; Pascal Augustin; Nathalie Grall; Mathieu Desmard; Nicolas Allou; Jean-Pierre Marmuse; Jean Guglielminotti
Journal:  Crit Care       Date:  2016-04-07       Impact factor: 9.097

Review 7.  Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.

Authors:  Matteo Bassetti; Jan J De Waele; Philippe Eggimann; Josè Garnacho-Montero; Gunnar Kahlmeter; Francesco Menichetti; David P Nicolau; Jose Arturo Paiva; Mario Tumbarello; Tobias Welte; Mark Wilcox; Jean Ralph Zahar; Garyphallia Poulakou
Journal:  Intensive Care Med       Date:  2015-03-20       Impact factor: 17.440
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.